Skip to main content

Advertisement

SpringerLink
Log in

Combined vindesine and razoxane shows antimetastatic activity in advanced soft tissue sarcomas

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Background Razoxane and vindesine were shown to suppress distant metastasis in animal systems. Both drugs affect main steps of the metastatic cascade. Therefore, a pilot study was performed to study the influence of these drugs on the dynamics of metastasis in advanced soft tissue sarcomas (STS). This study was now updated. Methods Twenty-three patients with unresectable (n = 7) and oligometastatic STS (n = 16) received a basic treatment with razoxane and vindesine supported by radiotherapy and occasionally by surgery. Long-term treatment was intended in patients with metastatic disease. The cumulative number of new metastases after 6 and 9 months were determined. Thirty-six patients with comparable stages of STS treated with contemporary chemotherapy served as non-randomized, retrospective controls. The prognostic parameters of the groups were comparable. Results In patients receiving razoxane and vindesine, the median number of new metastases after 6 months was 0 (range, 0–40) and after 9 months likewise 0 (0–70). The corresponding numbers in the control group were 4.5 (range, 0–40) and 9 (0–>100) (P < 0.001). The progression-free survival at 6 months was 74% in the study group and 23% in the controls. The median survival time from the occurrence of the first metastasis or the time of unresectability was 20+ months (range, 8–120+) versus 9 months (range, 2–252) (P < 0.001). The combined treatment was associated with a low to moderate toxicity. Conclusions Trimodal treatment with razoxane, vindesine, and radiotherapy is feasible in patients with unresectable primaries and early metastatic STS. The combination inhibits the development of remote metastases in a majority of the patients and prolongs survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rhomberg W, Hassenstein EOM, Gefeller D (1996) Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study. Int J Radiat Oncol Biol Phys 36:1077–1084

    PubMed  CAS  Google Scholar 

  2. Rhomberg W, Eiter H, Schmid F, Saely CH (2007) Razoxane and vindesine in advanced soft tissue sarcomas: impact on metastasis, survival and radiation response. Anticancer Res 27(5)

  3. De Vita VT Jr, Hellman S, Rosenberg SA (eds) (2001) Cancer principles & practice of oncology. JB Lippincott Comp, Philadelphia, pp 1879–1883

    Google Scholar 

  4. Storme GA, Schallier DC, De Neve WJ et al (1988) Vinblastine has radiosensitizing activity in limited squamous cell lung cancer. Int J Radiat Oncol Biol Phys 15(Suppl 1):222

    Google Scholar 

  5. Rhomberg W, Eiter H, Soltesz E et al (1990) Long term application of vindesine: toxicity and tolerance. J Cancer Res Clin Oncol 116:651–653

    Article  PubMed  CAS  Google Scholar 

  6. Atassi G, Dumont P, Vandendris M (1982) Investigation of the in vivo anti-invasive and anti-metastatic effect of desacetyl vinblastine amide sulphate or vindesine. Invasion Metastasis 2:217–231

    PubMed  CAS  Google Scholar 

  7. Mareel MM, Bracke ME, Boghaert ER (1986) Tumor invasion and metastasis: therapeutic implications? Radiother Oncol 6:135–142

    Article  PubMed  CAS  Google Scholar 

  8. Haug IJ, Siebke EM, Grimstad IA et al (1993) Simultaneous assessment of migration and proliferation of murine fibrosarcoma cells, as affected by hydroxyurea, vinblastine, cytochalasin B, razoxane and interferon. Cell Prolif 26:251–261

    PubMed  CAS  Google Scholar 

  9. Mareel MM, Storme GA, De Bruyne GK et al (1982) Vinblastin, vincristine and vindesine: antiinvasive effect on MO4 mouse fibrosarcoma cells in vitro. Eur J Cancer Clin Oncol 18:199–210

    Article  PubMed  CAS  Google Scholar 

  10. Hellmann K, Murkin GE (1974) Synergism of ICRF 159 and radiotherapy in the treatment of experimental tumors. Cancer 34:1033–1039

    Article  PubMed  CAS  Google Scholar 

  11. Tanabe K, Ikegami Y, Ishida R, Andoh T (1991) Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 51:4903–4908

    PubMed  CAS  Google Scholar 

  12. Karakiulakis G, Missirlis E, Maragoudakis ME (1989) Mode of action of razoxane: inhibition of basement membrane collagen-degradation by a malignant tumor enzyme. Methods Find Exp Clin Pharmacol 11:255–261

    PubMed  CAS  Google Scholar 

  13. Hellmann K, Burrage K (1969) Control of malignant metastases by ICRF 159. Nature 224:273–275

    Article  PubMed  CAS  Google Scholar 

  14. Le Serve AW, Hellmann K (1972) Metastases and the normalization of tumor blood vessels by ICRF-159: a new type of drug action. Br Med J 1:597–601

    Article  PubMed  CAS  Google Scholar 

  15. Hellmann K (2003) Dynamics of tumour angiogenesis: effect of razoxane-induced growth rate slowdown. Clin Exp Metastasis 20:95–102

    Article  PubMed  CAS  Google Scholar 

  16. Salsbury AJ, Burrage K, Hellmann K (1974) Histological analysis of the antimetastatic effect of 1,2-Bis (3,5-dioxo-piperazin-1-yl)-propane. Cancer Res 34:843–849

    PubMed  CAS  Google Scholar 

  17. Baker D, Constable W, Elkon D, Rinehart L (1981) The influence of ICRF 159 and levamisole on the incidence of metastases following local irradiation of a solid tumor. Cancer 48:2179–2183

    Article  PubMed  CAS  Google Scholar 

  18. Peters LJ (1975) A study of the influence of various diagnostic and therapeutic procedures applied to a murine squamous carcinoma on its metastatic behaviour. Br J Cancer 32(3):355–365

    PubMed  CAS  Google Scholar 

  19. Antman K, Crowley J, Balcerzak SP et al (1993) An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11:1276–1285

    PubMed  CAS  Google Scholar 

  20. Edmonson JH, Ryan LM, Blum RH et al (1993) Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11:1269–1275

    PubMed  CAS  Google Scholar 

  21. Santoro A, Tursz T, Mouridsen H et al (1995) Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first line treatment of advanced soft tissue sarcomas: a randomized study of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537–1545

    PubMed  CAS  Google Scholar 

  22. Rööser B, Attewell R, Berg NO, Rydholm A (1988) Prognostication in soft tissue sarcoma. A model with four risk factors. Cancer 61:817–823

    Article  PubMed  Google Scholar 

  23. Zagars GK, Ballo MT, Pisters PWT et al (2003) Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 57:739–747

    PubMed  Google Scholar 

  24. Komdeur R, Hoekstra HJ, van den Berg E et al (2002) Metastasis in soft tissue sarcomas: prognostic criteria and treatment perspectives. Cancer Metastasis Rev 21:167–183

    Article  PubMed  CAS  Google Scholar 

  25. Kerbel RS (2001) Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 19(Suppl):45s–51s

    PubMed  CAS  Google Scholar 

  26. Klement G, Baruchel S, Rak J et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15–R24

    Article  PubMed  CAS  Google Scholar 

  27. Hofland KF, Thougaard AV, Dejligbjerg M et al (2005) Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors. Clin Cancer Res 11:6722–6729

    Article  PubMed  CAS  Google Scholar 

  28. D’Adamo DR, Anderson SE, Albritton K et al (2005) Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 23:7135–7142

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Academic Teaching Hospital, Carinagasse 47, Feldkirch, 6800, Austria

    Walter Rhomberg & Helmut Eiter

  2. Department of Internal Medicine, General Hospital, Carl Pedenzstrasse 2, Bregenz, 6900, Austria

    Franz Schmid

  3. Department of Internal Medicine, Academic Teaching Hospital, Carinagasse 47, Feldkirch, 6800, Austria

    Christoph H. Saely

  4. VIVIT Institute, Feldkirch, Austria

    Christoph H. Saely

Authors
  1. Walter Rhomberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helmut Eiter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Franz Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christoph H. Saely
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Walter Rhomberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rhomberg, W., Eiter, H., Schmid, F. et al. Combined vindesine and razoxane shows antimetastatic activity in advanced soft tissue sarcomas. Clin Exp Metastasis 25, 75–80 (2008). https://doi.org/10.1007/s10585-007-9103-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-007-9103-9

Keywords

Search

Navigation